Intervention of Bladder Cancer by CAR-T

Exclusion Criteria

• •1. Any approved anti-cancer therapy within 3 weeks prior to initiation of study treatment
• •2. Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 28 days prior to enrollment
• •3. Active or untreated central nervous system (CNS) metastases as determined by computed tomography (CT) or magnetic resonance imaging (MRI) evaluation during screening and prior radiographic assessments
• •4. Leptomeningeal disease
• •5. Malignancies other than UBC within 5 years prior to Cycle 1, Day 1
• •6. Pregnant and lactating women
• •7. Significant cardiovascular disease
• •8. Severe infections within 4 weeks prior to infusion
• •9. Major surgical procedure other than for diagnosis within 4 weeks
• •10. History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins; known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation
• •11. History of autoimmune disease
• •12. Prior allogeneic stem cell or solid organ transplant
• •13. History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan
• •14. Positive test for human immunodeficiency virus (HIV) and/or active hepatitis B or hepatitis C or tuberculosis